Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sention licenses compounds from Merck

Executive Summary

Sention Inc. (develops treatments for cognitive impairment and CNS disorders) has exclusively licensed from Merck & Co. Inc. a group of compounds called metabotropic glutamate receptor (mGluR) antagonists to use in the development of potential therapeutics for Fragile X mental retardation.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register